Company Overview
About BillionToOne
BillionToOne is a leading molecular diagnostics company that has commercialized a proprietary technology platform—Quantitative Counting Templates (QCTs)—enabling detection and quantification of disease-related DNA at single base-pair resolution. This breakthrough in cell-free DNA (cfDNA) analysis underpins its two primary product lines: UNITY Screen for comprehensive prenatal genetic screening (covering carrier status, chromosomal conditions, and fetal risk) and Northstar Select for oncology therapy guidance and liquid biopsy.
Business Model & Competitive Advantage
The company completed a landmark IPO in November 2025, raising approximately $273M through the sale of 4.55 million shares at $60 each, with Class A common stock trading on the Nasdaq Global Select Market under the ticker BLLN. Prior to the IPO, BillionToOne had raised $130M in an oversubscribed Series D at a $1B+ valuation in June 2024. The company processed over 508,000 tests in the year ending June 2025, surpassing 1 million cumulative tests since launch.
Competitive Landscape 2025–2026
For FY2025, BillionToOne guided to $293–299M in revenue with positive GAAP operating income—a rare profitability milestone for a clinical-stage diagnostics company. The company has integrated its prenatal and oncology tests with Epic EHR, extending clinical reach into large health systems. BillionToOne's single-molecule precision positions it as a platform diagnostic company, with QCT technology applicable across an expanding range of genetically driven diseases.
Key Differentiators
Market Leader
BillionToOne is recognized as a market leader in the Life Sciences & BioTech sector, demonstrating strong industry presence and customer trust.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Compare BillionToOne with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from BillionToOne? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim BillionToOne Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention BillionToOne vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →